



**FOR IMMEDIATE RELEASE**  
**NEWS RELEASE**  
**TSX Venture: AMF**

**AMORFIX LIFE SCIENCES ISSUES STOCK OPTIONS**

TORONTO, ON, May 25, 2006 – Amorfix Life Sciences Ltd. reports that it has granted 100,000 options to an investor relations consultant. The options will vest over one year and are exercisable at \$1.15 per share for a period of one year after vesting. Amorfix also reports that it granted 137,500 options to senior officers on April 26, 2006 that are exercisable at \$0.85 per share for a five year period. The option grants are subject to acceptance for filing by the TSX Venture exchange.

**About Amorfix**

Amorfix is an emerging theranostics company focused on the diagnosis and treatment of neurodegenerative diseases, where aggregated misfolded proteins (AMPs) are prevalent. These include aggregated misfolded prion protein which makes up “prions,” the infectious agents of the Transmissible Spongiform Encephalopathies (TSE), such as Bovine Spongiform Encephalopathy (BSE or "mad cow disease") and the human form, variant Creutzfeldt-Jakob Disease (vCJD), as well as degenerative diseases such as Alzheimer’s Disease (AD), Amyotrophic Lateral Sclerosis (ALS) and Parkinson’s Disease (PD). Amorfix was formed to commercialize epitope protection (EP) technologies and related discoveries to become the world leader on AMP diseases. The company will use this new knowledge to develop diagnostic kits, therapeutics and preventative therapies for AMP diseases.

For further information, please contact:

Dr. George Adams, President and CEO  
Amorfix Life Sciences Ltd.  
416-482-3812  
[info@amorfix.com](mailto:info@amorfix.com)

James Parsons, CFO  
Amorfix Life Sciences Ltd.  
416-482-3814

**The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Actual future results may differ materially from those contemplated. The risks, uncertainties and other factors that could influence the actual results are described in documents filed with regulatory authorities.**